Filings set for Takeda's ixazomib on Phase III data
This article was originally published in Scrip
Takeda is set to file for approval worldwide of its leading oral proteasome inhibitor ixazomib in multiple myeloma on the basis of encouraging interim data from the Phase III TOURMALINE-MM1 study.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.